Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The pact gives Roche access to PureTech’s milk-derived exosome technology in return for up to $36 million in near-term payments.
Human Longevity CFO/COO departs after scandal; Sangamo loses another top executive; McCann Health fires chief creative for conduct violation and more.
AMPLEXOR Life Sciences: Helping Life Sciences Firms Optimize Routine Document Production
In this week's EuroBiotech Report, European drug developers strike a string of deals, UCB refiles romosozumab and more.
In our EuroBiotech roundup this week, Cassiopea posts more data, Takeda inks deal with leon-nanodrugs and Silence names CEO.
The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need…
A startup called Macregen has licensed an eye drop that can penetrate the cells of the retina and deliver a treatment for AMD.
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.
After a string of pipeline failures, Vical has called in advisers to help decide the future of the company.
A capsaicin-based therapy developed by University of Wyoming scientists showed promise in mouse models of obesity.
Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
Novartis will take MOR106 forward in atopic dermatitis and other indications, handing over up to €850 million in milestones as it goes.